Insulet Corporation (PODD) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PODD Revenue Growth
Revenue Breakdown (FY 2025)
PODD's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
PODD Revenue Analysis (2014–2025)
As of May 8, 2026, Insulet Corporation (PODD) generated trailing twelve-month (TTM) revenue of $2.90 billion, reflecting explosive growth of +33.9% year-over-year. The most recent quarter (Q1 2026) recorded $761.7 million in revenue, down 2.8% sequentially.
Looking at the longer-term picture, PODD's 5-year compound annual growth rate (CAGR) stands at +24.5%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $2.71 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows PODD's business is primarily driven by International Omnipod (99%), and Drug Delivery (1%). With over half of revenue concentrated in International Omnipod, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including DXCM (+16.2% YoY), TNDM (-6.8% YoY), and NVCR (+8.5% YoY), PODD has outperformed the peer group in terms of revenue growth. Compare PODD vs DXCM →
PODD Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PODDCurrent | $2.9B | +33.9% | +24.5% | 17.5% | |
 DXCM | $4.7B | +16.2% | +19.3% | 19.6% | |
 TNDM | $1.0B | -6.8% | +15.3% | -7.7% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 ITGR | $1.8B | +6.0% | +11.5% | 11.3% | |
 ABT | $42.0B | +6.4% | +5.6% | 16.3% |
PODD Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.71B | +30.7% | $1.94B | 71.6% | $473.8M | 17.5% |
| 2024 | $2.07B | +22.1% | $1.45B | 69.8% | $308.9M | 14.9% |
| 2023 | $1.70B | +30.0% | $1.16B | 68.3% | $220.0M | 13.0% |
| 2022 | $1.31B | +18.8% | $805.6M | 61.7% | $37.6M | 2.9% |
| 2021 | $1.10B | +21.5% | $752.1M | 68.4% | $126.0M | 11.5% |
| 2020 | $904.4M | +22.5% | $582.3M | 64.4% | $51.5M | 5.7% |
| 2019 | $738.2M | +30.9% | $480.3M | 65.1% | $50.0M | 6.8% |
| 2018 | $563.8M | +21.6% | $370.2M | 65.7% | $27.4M | 4.9% |
| 2017 | $463.8M | +26.4% | $277.2M | 59.8% | $-7,400,000 | -1.6% |
| 2016 | $367.0M | +39.1% | $211.1M | 57.5% | $-10,704,000 | -2.9% |
Full PODD Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See PODD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PODD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PODD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPODD — Frequently Asked Questions
Quick answers to the most common questions about buying PODD stock.
Is PODD's revenue growth accelerating or slowing?
PODD revenue is accelerating at +33.9% year-over-year, exceeding the 5-year CAGR of +24.5%. TTM revenue reached $2.9B. Growth momentum has increased versus prior periods.
What is PODD's long-term revenue growth rate?
Insulet Corporation's 5-year revenue CAGR of +24.5% reflects the sustained expansion pattern. Current YoY growth of +33.9% is above this long-term average.
How is PODD's revenue distributed by segment?
PODD reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.